Loading clinical trials...
Loading clinical trials...
A Multi-center, Open-label Trial Investigating the Efficacy and Safety of Continued Treatment With Tisotumab Vedotin in Patients With Solid Tumors Known to Express Tissue Factor.
Conditions
Interventions
Tisotumab Vedotin
Locations
4
United States
Brian Slomovitz
Miami, Florida, United States
Johann de Bono
Chelsea, United Kingdom
Beatson Cancer Centre
Glasgow, United Kingdom
Fiona Thistlethwaite
Manchester, United Kingdom
Start Date
August 23, 2017
Primary Completion Date
January 10, 2019
Completion Date
January 10, 2019
Last Updated
November 4, 2021
NCT06964009
NCT07276360
NCT05990426
NCT07428330
NCT06051695
NCT07318727
Lead Sponsor
Seagen Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions